用于呼吸系统疾病的药物递送系统：肺部给药治疗创新见解
Drug Delivery Systems for Respiratory Diseases: Insights into the Therapeutic Innovations for Pulmonary Administration.
作者信息
Govender Mershen, Choonara Yahya E
机构信息
Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
出版信息
Pharmaceutics. 2025 Apr 22;17(5):539. doi: 10.3390/pharmaceutics17050539.
Abstract
Respiratory issues, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, and respiratory infections, are amongst the most common and debilitating medical conditions experienced worldwide, affecting millions of patients annually [...].
摘要
呼吸系统疾病，如哮喘、慢性阻塞性肺疾病（COPD）、肺纤维化、肺动脉高压和呼吸道感染，是全球最常见且使人衰弱的医疗状况之一，每年影响数百万患者[……]
相似文献
1
Drug Delivery Systems for Respiratory Diseases: Insights into the Therapeutic Innovations for Pulmonary Administration.用于呼吸系统疾病的药物递送系统：肺部给药治疗创新见解
Pharmaceutics. 2025 Apr 22;17(5):539. doi: 10.3390/pharmaceutics17050539.
2
Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease.哮喘和慢性阻塞性肺疾病的吸入疗法。
Curr Pharm Des. 2021;27(12):1469-1481. doi: 10.2174/1389201021666201126144057.
3
Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.用于阻塞性和限制性呼吸系统疾病的寡核苷酸疗法。
Molecules. 2017 Jan 17;22(1):139. doi: 10.3390/molecules22010139.
4
PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases.PLGA 基微/纳米粒子：在呼吸系统疾病中的应用概述。
Int J Mol Sci. 2023 Feb 22;24(5):4333. doi: 10.3390/ijms24054333.
5
Advancing Treatment Strategies: A Comprehensive Review of Drug Delivery Innovations for Chronic Inflammatory Respiratory Diseases.推进治疗策略：慢性炎症性呼吸道疾病药物递送创新的全面综述
Pharmaceutics. 2023 Aug 17;15(8):2151. doi: 10.3390/pharmaceutics15082151.
6
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范（2023年）]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
7
Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.哮喘和慢性阻塞性肺疾病成人患者呼吸道合胞病毒病负担：一项系统文献综述
Curr Allergy Asthma Rep. 2025 Feb 25;25(1):14. doi: 10.1007/s11882-025-01194-w.
8
Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems.壳聚糖及其衍生物在基于纳米载体的肺部药物递送系统中的应用。
Pharm Nanotechnol. 2017;5(4):243-249. doi: 10.2174/2211738505666170808095258.
9
Factors affecting the choice of therapeutic regimens in asthma and chronic obstructive pulmonary disease patients and patient adherence to the therapies prescribed.影响哮喘和慢性阻塞性肺疾病患者治疗方案选择及患者对所开处方治疗的依从性的因素。
Postepy Dermatol Alergol. 2019 Apr;36(2):202-210. doi: 10.5114/ada.2018.76144. Epub 2018 Apr 3.
10
The role of microRNAs in chronic respiratory disease: recent insights.microRNAs 在慢性呼吸疾病中的作用：最新研究进展。
Biol Chem. 2018 Feb 23;399(3):219-234. doi: 10.1515/hsz-2017-0249.
本文引用的文献
1
Modified-Release Pulmonary Delivery Systems for Labile Bioactives: Design, Development, and Applications.用于不稳定生物活性物质的缓释肺部给药系统：设计、开发与应用
Pharmaceutics. 2025 Apr 3;17(4):470. doi: 10.3390/pharmaceutics17040470.
2
Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis.用于呼吸系统疾病治疗中药物递送的纳米结构：当前趋势综述及其比较分析
J Drug Deliv Sci Technol. 2022 Apr;70:103219. doi: 10.1016/j.jddst.2022.103219. Epub 2022 Mar 5.
3
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.用于治疗传染性肺病的肺部递药策略路线图。
J Nanobiotechnology. 2022 Mar 3;20(1):101. doi: 10.1186/s12951-022-01307-x.
4
Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?纳米药物向肺部的递送——通过吸入或其他途径，以及在微米级药物基本足够的情况下为何还要使用纳米级药物？
Adv Drug Deliv Rev. 2022 Apr;183:114173. doi: 10.1016/j.addr.2022.114173. Epub 2022 Feb 22.
5
Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.克服肺部给药相关生物屏障的策略。
Pharmaceutics. 2022 Jan 27;14(2):302. doi: 10.3390/pharmaceutics14020302.
6
Global Impact of Respiratory Disease: What Can We Do, Together, to Make a Difference?呼吸系统疾病的全球影响：我们能共同做些什么来产生影响？
Chest. 2022 May;161(5):1153-1154. doi: 10.1016/j.chest.2022.01.014. Epub 2022 Jan 17.
7
Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.慢性阻塞性肺疾病（COPD）的成本分析：一项系统综述。
Health Econ Rev. 2021 Aug 17;11(1):31. doi: 10.1186/s13561-021-00329-9.
8
The Nanosystems Involved in Treating Lung Cancer.用于治疗肺癌的纳米系统。
Life (Basel). 2021 Jul 13;11(7):682. doi: 10.3390/life11070682.
9
Recent applications and strategies in nanotechnology for lung diseases.纳米技术在肺部疾病中的最新应用与策略
Nano Res. 2021;14(7):2067-2089. doi: 10.1007/s12274-020-3180-3. Epub 2021 Jan 8.
10
Nanotechnology in pulmonary medicine.纳米技术在肺部医学中的应用。
Curr Opin Pharmacol. 2021 Feb;56:85-92. doi: 10.1016/j.coph.2020.11.002. Epub 2020 Dec 17.
Zotero 插件